Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The primary objective of this trial was to demonstrate, based on the estimated glomerular filtration rate (eGFR), superior renal function at month 12 after conversion of maintenance kidney transplant patients from calcineurin inhibitor (CNI) therapy to everolimus, compared to continuing a standard CNI regimen.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Nephrol.

Title: Clinical nephrology

ISSN: 0301-0430

ISSN (Print): 0301-0430

Publication date (Electronic): Jan 2015

Volume: 83

Issue: 1

Affiliations

[1 ] Department of Nephrology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Department of Nephrology and Transplantation Medicine, Westpfalz- Klinikum, Kaiserslautern, Department of Nephrology, Heidelberg University Hospital, Heidelberg, Department of Nephrology and Hypertensiology, Hannover Medical School, Hannover, Department of Transplantation, Division of Internal Medicine and Nephrology, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Department of Internal Medicine D, Transplant Nephrology, University of Münster, Münster, Novartis Pharma GmbH, Nuernberg, Department of Nephrology, Medical Clinic Köln-Merheim, Cologne, Germany, and APOLLO Study Group.

Article

Publisher Item ID: 12908

PubMed ID: 25512099

SO-VID: 2b9c448f-2657-4abb-971a-ab69dd274db5

History

Data availability:

Comments

Comment on this article

Cited by 11

See all cited by